2,274 AbbVie Inc. $ABBV Shares Bought by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH increased its holdings in AbbVie Inc. (NYSE:ABBV) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 210,990 shares of the company’s stock after buying an additional 2,274 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in AbbVie were worth $55,193,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Burk Holdings LLC bought a new stake in shares of AbbVie during the 2nd quarter valued at $30,000. Marquette Asset Management LLC boosted its stake in AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the period. Abound Financial LLC bought a new position in AbbVie in the 4th quarter worth about $32,000. Principia Wealth Advisory LLC boosted its stake in AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after purchasing an additional 44 shares during the period. Finally, Merkkuri Wealth Advisors LLC purchased a new position in AbbVie during the 1st quarter valued at about $34,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by insiders.

AbbVie Price Performance

Shares of ABBV opened at $283.58 on Thursday. The firm’s 50 day simple moving average is $261.16 and its 200 day simple moving average is $238.38. The company has a market capitalization of $501.03 billion, a P/E ratio of 80.11, a P/E/G ratio of 1.25 and a beta of 0.24. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $285.40.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 13.95 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: New Phase 3 AFFIRM data showed subcutaneous SKYRIZI improved clinical and endoscopic outcomes in patients with moderately to severely active Crohn’s disease. The results could support regulatory review of a more convenient formulation and strengthen AbbVie’s post-Humira growth outlook. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and maintained a $280 price target, while Erste Group raised its FY2027 EPS estimate to $16.34 from $16.19 and kept a Buy rating. RBC Reaffirms Outperform Rating
• Positive Sentiment: Unusually heavy call-option activity—86,296 calls purchased, roughly 445% above average volume—signals increased bullish speculative interest, although options activity is not a fundamental indicator.
• Positive Sentiment: Healthcare stocks broadly rallied, providing a favorable sector backdrop. Investors are also looking ahead to AbbVie’s October 30 earnings report, with expectations that Rinvoq, Skyrizi and Vraylar will support revenue growth. Lilly, Merck, AbbVie Stocks Surge

Analyst Upgrades and Downgrades

Several brokerages recently commented on ABBV. UBS Group boosted their price objective on shares of AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research note on Tuesday, October 6th. Rothschild & Co Redburn upped their target price on shares of AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Canaccord Genuity Group increased their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and raised their price target for the company from $235.00 to $300.00 in a report on Thursday, August 13th. Finally, Cantor Fitzgerald boosted their price target on shares of AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $277.18.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.